Patheon has closed the acquisition of IRIX Pharmaceuticals, a company that specialises in making difficult to manufacture active pharmaceutical ingredients (API) for drugs from early and late development, through to commercial launch.
With this acquisition, Patheon will establish a North American presence for comprehensive API development and manufacturing to address customers’ most challenging needs for drugs in all development phases.